Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
29.13
+0.10 (0.34%)
At close: Oct 28, 2025, 4:00 PM EDT
29.13
0.00 (0.00%)
Pre-market: Oct 29, 2025, 4:18 AM EDT
Genmab Revenue
Genmab had revenue of $925.00M in the quarter ending June 30, 2025, with 18.74% growth. This brings the company's revenue in the last twelve months to $3.65B, up 32.97% year-over-year. In the year 2024, Genmab had annual revenue of $2.99B with 22.32% growth.
Revenue (ttm)
$3.65B
Revenue Growth
+32.97%
P/S Ratio
4.92
Revenue / Employee
$1,359,762
Employees
2,682
Market Cap
17.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.99B | 545.24M | 22.32% |
| Dec 31, 2023 | 2.44B | 358.99M | 17.23% |
| Dec 31, 2022 | 2.08B | 796.62M | 61.88% |
| Dec 31, 2021 | 1.29B | -374.23M | -22.52% |
| Dec 31, 2020 | 1.66B | 855.79M | 106.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
GMAB News
- 5 days ago - Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS - Business Wire
- 8 days ago - Why Is Genmab Stock Trading Lower On Monday? - Benzinga
- 10 days ago - Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - Business Wire
- 14 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025 - GlobeNewsWire
- 4 weeks ago - MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS - Business Wire
- 4 weeks ago - Genmab A/S (GMAB) M&A Call Transcript - Seeking Alpha
- 4 weeks ago - Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough - Benzinga
- 4 weeks ago - This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired. - Barrons